Autopsy report · NCT03225924
Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy
Cause of deathFunding or business
“Stop of drug development”
Life of this trial
- Ran for about 2 years 3 months before it stopped.
- 25 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- The Lymphoma Academic Research Organisation
- Sponsor type
- University, hospital or other
- Conditions
- DLBCL
- Interventions
- Entospletinib; Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone
- Participants
- 25
- Sites
- 27
- Countries
- Belgium, France
Trials that died the same way
- Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer
“Drug development stopped” - Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo
“Changes in drug development plans” - Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer
“Drug sponsor stopped drug manufacture due to toxicity issues from other studies” - Panobinostat/Velcade in Multiple Myeloma
“This study was terminated because the drug company stopped making the study drug” - A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
“Company decided not to pursue the development of this drug in this patient population at this time”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.